Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CRBU Caribou Biosciences
7.350-0.090-1.21%
Close
02/07 16:00 ET
7.3500.0000.00%
Post Mkt Price 02/07 16:10 ET
High
7.500
Open
7.420
Turnover
3.83M
Low
7.150
Pre Close
7.440
Volume
522.16K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwit
Caribou Biosciences, Inc. (NASDAQ:CRBU) Insiders Must Be Happy They Sold Stock as Market Cap Drops to US$392m
Insiders at Caribou Biosciences, Inc. (NASDAQ:CRBU) sold US$108k worth of stock at an average price of US$10.80 a share over the past year, making the most of their investment. After the stock price
Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU) and Intercept Pharma (ICPT)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Caribou Biosciences, Inc. - CRBU
New York, New York--(Newsfile Corp. - January 7, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such i
Investors in Caribou Biosciences (NASDAQ:CRBU) From a Year Ago Are Still Down 46%, Even After 11% Gain This Past Week
Global CAR T-Cell Therapy Market Report to 2031 - Featuring Autolus Therapeutics, Bluebird Bio, Bristol-Myers Squibb and Caribou Biosciences Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "CAR T-Cell therapy Market By Drug type, By Indication, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMark
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou's
Brookline Capital Markets Sticks to Their Buy Rating for Caribou Biosciences (CRBU)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
New York, New York--(Newsfile Corp. - December 30, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of
Company Overview
More
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
CEO： Dr. Rachel Haurwitz, PhD
Market： NASDAQ
Listing Date： 07/23/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet